Medline (NASDAQ:MDLN – Get Free Report) had its target price lifted by stock analysts at Barclays from $43.00 to $45.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 21.56% from the stock’s current price.
MDLN has been the subject of a number of other research reports. BTIG Research reiterated a “buy” rating and issued a $55.00 price target on shares of Medline in a research note on Thursday, November 5th. William Blair restated an “outperform” rating on shares of Medline in a research note on Wednesday, September 23rd. BMO Capital Markets restated an “outperform” rating and set a $47.00 price objective on shares of Medline in a research note on Thursday, August 6th. Stifel Nicolaus dropped their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Citigroup raised their target price on shares of Medline from $45.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Twenty-three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.15.
Get Our Latest Report on Medline
Medline Trading Down 2.2%
Medline (NASDAQ:MDLN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. Equities research analysts predict that Medline will post 1.58 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the sale, the insider owned 20,231,483 shares in the company, valued at $715,182,924.05. The trade was a 11.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 6,348,676 shares of company stock worth $224,525,137 over the last 90 days. 0.81% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Medline
A number of hedge funds have recently added to or reduced their stakes in MDLN. American Century Companies Inc. acquired a new stake in shares of Medline during the 3rd quarter worth $6,283,000. Kentucky Retirement Systems Insurance Trust Fund lifted its holdings in shares of Medline by 10.0% during the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 11,431 shares of the company’s stock worth $397,000 after acquiring an additional 1,036 shares during the period. Kentucky Retirement Systems boosted its position in shares of Medline by 12.7% during the 3rd quarter. Kentucky Retirement Systems now owns 28,241 shares of the company’s stock worth $980,000 after acquiring an additional 3,192 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Medline by 36.8% in the 3rd quarter. Allworth Financial LP now owns 1,439 shares of the company’s stock valued at $50,000 after purchasing an additional 387 shares in the last quarter. Finally, Beck Mack & Oliver LLC acquired a new position in shares of Medline during the 3rd quarter worth $4,245,000.
Top Medline Stories
Investors following MDLN have been watching these stories:
- Positive Sentiment: Barclays raised its price target to $45 from $43 and maintained an “overweight” rating, implying substantial upside from the cited share price. Barclays rating information
- Positive Sentiment: Zacks Research upgraded Medline from “strong sell” to “hold,” a less bearish assessment. Zacks Research rating information
- Negative Sentiment: Medline reported additional deaths associated with its electric-bed recall, raising potential safety, legal and reputational concerns. Report on Medline bed recall
About Medline
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Further Reading
- Five stocks we like better than Medline
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
